Reviewing Gilead Sciences (NASDAQ:GILD) and Pharvaris (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS) and Gilead Sciences (NASDAQ:GILD) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Pharvaris and Gilead Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1	2	10	1	2.79
Gilead Sciences	0	4	25	0	2.86

Pharvaris currently has a consensus target price of $50.08, suggesting a potential upside of 43.75%. Gilead Sciences has a consensus target price of $158.04, suggesting a potential upside of 18.77%. Given Pharvaris’ higher probable upside, analysts plainly believe Pharvaris is more favorable than Gilead Sciences.

Risk & Volatility

Pharvaris has a beta of -2.31, meaning that its share price is 331% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Profitability

This table compares Pharvaris and Gilead Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Gilead Sciences	-10.64%	-2.11%	-0.75%

Valuation & Earnings

This table compares Pharvaris and Gilead Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79 million	($3.18)	-10.96
Gilead Sciences	$29.44 billion	5.60	$8.51 billion	($2.67)	-49.84

Gilead Sciences has higher revenue and earnings than Pharvaris. Gilead Sciences is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.7% of Gilead Sciences shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Pharvaris on 10 of the 14 factors compared between the two stocks.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.